

In silico Discovery of Novel FXa Inhibitors by Pharmacophore Modeling and Molecular Docking




Yinglan Pu · Hui Liu · Yeheng Zhou ·
Jiale Peng · Yaping Li · Penghua Li ·
Yingying Li · Xingyong Liu · Li Zhang

Received: 14 March 2017 / Accepted: 5 April 2017 / Published online: 2 June 2017
© The Author(s) 2017. This article is an open access publication

Abstract Coagulation Factor Xa (FXa) is the crucial enzyme at the convergent point of the intrinsic and extrinsic coagulation pathways. The inhibition of FXa is an effective approach against thrombotic diseases. In the present study, a specific strategy is reported to discover 10 novel FXa inhibitors based on ligand-based (pharmacophore) virtual screening and molecular docking analysis from a dataset of specs (containing 220,000 molecules). The binding modes analysis provide insights into the contribution of particular structural moieties of the compounds towards their activity against FXa, and 10 novel structural compounds were discovered as potent candidate molecules. This work could be helpful in further design and development of FXa inhibitors.

Graphical Abstract



Keywords FXa · Thrombotic diseases · Pharmacophore · Docking

Y. Pu · H. Liu · Y. Zhou · J. Peng · Y. Li · P. Li · Y. Li ·
X. Liu (✉) · L. Zhang (✉)
School of Chemical Engineering, Sichuan University of Science
& Engineering, Zigong, China
e-mail: zhangli19700554@163.com

1 Introduction

FXa, a vitamin K-dependent serine protease, is a key enzyme in the coagulation cascade [1]. It is located at the convergence of the extrinsic and the intrinsic activation

pathways [2]. Due to it is upstream of thrombin, FXa can promote the production of new thrombin without causing bleeding symptoms or affecting the existing thrombin [3]. Therefore, FXa is recognized as an ideal and attractive target for anticoagulation therapy in the development of new drugs, which make FXa inhibitors become a hot topic of anticoagulant research [4].

Thrombotic diseases, such as myocardial infarction and stroke, could cause organ tissue ischemia, necrosis, seriously endanger human health [5, 6]. Anticoagulants are widely used in the prevention and treatment of thromboembolic disorders. Pre-existing anticoagulant drugs, such as unfractionated heparin, low molecular weight heparin, warfarin, have some limitations: narrow treatment window, slow onset, causing bleeding [7–12]. Owing to above reasons, these drugs have been gradually replaced by anticoagulant drugs targeting a single coagulation factor [13].

In order to develop novel FXa inhibitors, we have developed a comprehensive and rational protocol. Herein, a series of new hits were discovered based on ligand-based screening and molecular docking (Fig. 1). The specs database was first refined according to the Rule of five and Veber rules. Secondly, the pharmacophore features based on the known inhibitors were employed to query the new potent inhibitors. Thirdly, docking strategy was used to screen the remained top 10000 compounds. Eventually, 10 potential FXa inhibitors, which were obtained according to the docking score list, were further studied on their interactions with FXa.

2 Materials and Methods

Virtual screening is one of the most widely applied methods to discover novel scaffolds for various targets. Generally, it can be categorized into two major types: structure-




Fig. 1 Overview of the workflow

based method and ligand-based method [14]. In the present research, to optimize the development of new FXa inhibitors, docking strategy and ligand-based pharmacophore were used in combination to identify the novel potential FXa inhibitors.

The GOLD 5.2.2 (Genetic Optimization of Ligand Docking) [15], incorporated installed on Intel(R) Xeon(R) CPU 2.30 GHz, 32 CPU, Core 8 Dell server with Linux operating systems, was used for molecular docking studies. While pharmacophore was carried out using pharmacophore module from Discovery Studio Version 4.0 (DS 4.0, Accelrys Inc., San Diego, CA), which is commercially available software and widely used in the drug discovery. The specs database consists of about 220000 small molecules, downloaded from specs official website (www.specs.net). Figure 1, including molecular docking and ligand-based (HipHop pharmacophore) screening, showed the working flow chart of this study.

2.1 Dataset

A dataset of 24 FXa inhibitors were collected from different publications, 10 of which were selected as training set to generate common features (Fig. 2). The other 14 molecules were treated as active compounds of test set. While the 14 inactives were randomly chosen from FXa-decoys set reported by University of California, San Francisco (<http://dud.docking.org>). For each compound, the geometries were corrected, atoms were typed and energy mini-mization was performed using DS 4.0.

The X-ray crystal structure of FXa complex with an inhibitor M55125 (PDB ID: 1IQI) [16] with high resolution of 2.9 Å was downloaded from the RCSB Protein Data Bank (www.rcsb.org). Before docking, the obtained protein was prepared in the Accelrys DS 4.0. The water was removed, some other co-crystallized small molecules were deleted, hydrogens were added, and the whole structure was optimized using SYBYL 2.0.

2.2 Pharmacophore Generation and Validation

The HipHop pharmacophore model was developed using Pharmacophore module of DS 4.0. The training set molecules were considered to generate conformation. The parameters were set as follows. First, the Principal and MaxOmitFeat parameters were set as 2 and 0, respectively. Then, on the feature mapping procedure step, all the features were chosen, the Minimum/Maximum Features parameter was set as 0 and 5. In the final step, according to the details of results of the previous step, 6 features were selected to generate the common feature pharmacophore which were HB-ACCEPTOR, HB_ACCEPTOR_lipid, RING_AROMATIC, HBA_HEAVY, HBA_PROJECTION, and HBD_1. HB-ACCEPTOR represents




Fig. 2 Chemical structures of the training set compounds

Hydrogen-Bonding Acceptor, HB_ACCEPTOR_lipid represents lipidic hydrogen bond acceptor, RING_AROMATIC represents ring aromatic, HBA_HEAVY represents the heavy atom of a hydrogen bond acceptor, HBA_PROJECTION represents the projection point of a hydrogen bond acceptor, and HBD_1 represented hydrogen bond donor and matching an aromatic carbon with a hydrogen. The rest of the parameters were set at default values.

Finally, 10 hypotheses (Hypo) were generated and validated by test set. Validation is an essential step to pick out the most suitable Hypo from the ten pharmacophore models. In this work, the developed pharmacophore hypotheses were validated by heat map, and the Hypotheses 4 was turned out to be the best model was then used to virtual screening.

2.3 Virtual Screening Based on Pharmacophore Modeling

Hypo 4, the best pharmacophore, was selected to screen the database. The Number of Conformations was set to 200 and the Conformation Method was set to BEST. While Minimum Interfeature Distance was set to 2, Limit Hits was set to First N and Maximum Hits was set to 500. Most

of other parameters were set as default. Eventually, the top 10000 (pharmacophore) molecules were chosen to the docking process.

2.4 Molecular Docking

The molecular docking in this study was carried out utilizing the crystal structure of FXa (PDB ID: 1IQI). The active pocket was defined by a grid with the outer box dimensions of 8Å centered on the crystalized ligand. Before screening, we've tried a variety of scoring functions to obtain the optimal parameters. Among them, when the inner-ligand was re-docked into the binding pocket with the scoring function of Chemplp, the root mean square deviation (RMSD) of all atoms between docked pose and original conformations was minimum (0.410 Å), indicating that the parameters for docking simulation were good in reproducing the X-ray crystal structure. The Chemscore Kinase and ChemPLP were applied as template and scoring function. Each of the top 10000 (pharmacophore) molecules was docked 30 times. Other docking operations were performed with the default settings. Finally, 200 molecules with the highest docking scores were reserved for the further cluster analysis.

Table 1 Structures of 10 compounds against FXa











No.	MW	Structure	No.	MW	Structure
M1	613.5		M2	580.68	
M3	444.91		M4	648.43	
M5	410.51		M6	463.6	
M7	573.15		M8	653.58	

Table 1 continued

No.	MW	Structure	No.	MW	Structure
M9	644.77		M10	480.56	




Fig. 3 HipHop pharmacophore validation. **a)** heatmap of the ten hypotheses. **b)** the chemical features and 3D structure of Hypo 4 binding with ligand of training set. Two colors represented two pharmacophore features, green represented HBA, magenta represented HBD

2.5 Cluster Analysis

After the molecular docking, the top-ranked 200 molecules were further analyzed using a series of analysis methods,

visual inspection of binding mode and the ligand fitness of the pharmacophore. Finally, 10 compounds, which have structural diversity, proper binding modes and good fitness, were considered as the fit conformation.




Fig. 4 The binding mode of hits with FXa carried out by SYBYL. Grey sticks were represented the *ligand*, and blue and green represented active cave




Fig. 5 3D structure of Hypo 4 binding with hits carried out by DS. Two colors represented two pharmacophore features, green represented HBA, magenta represented HBD

ring of M1 is the main group which contributes to the hydrogen bond donor (HBD) interaction dominantly. However, 2 hydrogen bond acceptor (HBA) interactions were provided by the atom O of furan ring and methoxy. In M2, 2 atoms O of carbonyl figured as HBA, while HBD was offered by naphthalene. In M3, 2 atoms O of carbonyl and benzene ring provided 2 HBA and HBD, respectively. M4 and M10 were similar to M2. The atom O of carbonyl and methoxy were HBA(in M5, M6), hydroxyl (in M5) and benzene ring(in M6) were HBD. The atom N and O were closely related to HBA features, and cyclohexane was HBD features (in M7). In M8, the atom S and N were closely related to HBD. Similarly, M9 got well with the model. The result of interactions 10 compounds with FXa were also investigated to testified the FXa inhibition of 10 molecules (Fig. 6). As it demonstrated, compounds were surrounded by E97, Y99, F174, I175, D189, G216, Y228. Hydrogen bonds, π - π stacking and multiple non-bonding interactions were formed between these 10 inhibitors and FXa. Among them, Y99, F97, I175, G216 were the residues involved in H-bond formation, F174, D189, Y228 were the residues involved in Pi-bond interactions and Van Der Waals interactions. These amino acids which were proved by other references were vital active residues of FXa. The interactions represented that compounds have high affinity to FXa, which also allowed compounds to develop to be a better inhibitor of FXa.

4 Conclusions

In order to search effective FXa inhibitors, a rational combination strategy containing molecular docking and pharmacophore model based on the known FXa inhibitors was adopted in this study. Consequently, we discovered 10 molecules as the novel FXa inhibitors. Furthermore, the interaction modes between FXa inhibitors and 10 compounds were disclosed through clustering analysis, pharmacophore modeling and molecular docking studies. It showed that they could bind with the structure of FXa stably through some bonding interactions and non-bonding interactions. Among them, E97, Y99, F174, I175, D189, G216, Y228 were suggested to be crucial residues due to the formation of hydrogen bonds and π - π stacking with the ligands. All in all, these compounds are promising FXa inhibitors and provide a foundation for the further exploring for the treatment of thrombotic diseases.

Acknowledgements We gratefully thank financial assistance from the Science and Technology Innovation Talent Project of Sichuan province (Grant number 2016073).

Conflict of interest The authors declare no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. R.G. Macfarlane, *Nature* **202**, 498–499 (1964)
2. R.L. Adams, R.J. Bird, *Nephrology* **14**, 462–470 (2009)
3. C.B. Granger, J.H. Alexander, J.J.V. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, H.R. Al-Khalidi, J. Ansell, D. Atar, A. Avezum, M.C. Bahit, R. Diaz, J.D. Easton, J.A. Ezekowitz, G. Flaker, D. Garcia, M. Ghalib, B.J. Gersh, S. Golitsyn, S. Goto, A.G. Hermosillo, S.H. Hohnloser, J. Horowitz, P. Mohan, P. Jansky, B.S. Lewis, J.L. Lopez-Sendon, P. Pais, A. Parkhomenko, F.W.A. Verheugt, J. Zhu, L. Wallentin, *N. Engl. J. Med.* **365**, 981–992 (2011)
4. T.J. Milling Jr., S. Kaatz, *Am. J. Emerg. Med.* **34**, 39–45 (2016)
5. K.L. Furie, S.E. Kasner, R.J. Adams, G.W. Albers, R.L. Bush, S.C. Fagan, J.L. Halperin, S.C. Johnston, I. Katzan, W.N. Kernan, P.H. Mitchell, B. Ovbiagele, Y.Y. Palesch, R.L. Sacco, L.H. Schwamm, S. Wassertheil-Smoller, T.N. Turan, D. Wentworth, *The American Heart Association/American Stroke Association, Stroke* **42**, 227–276 (2011)
6. M. Writing Group, V.L. Roger, A.S. Go, D.M. Lloyd-Jones, E.J. Benjamin, J.D. Berry, W.B. Borden, D.M. Bravata, S. Dai, E.S. Ford, C.S. Fox, H.J. Fullerton, C. Gillespie, S.M. Hailpern, J.A. Heit, V.J. Howard, B.M. Kissela, S.J. Kittner, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, D.M. Makuc, G.M. Marcus, A. Marelli, D.B. Matchar, C.S. Moy, D. Mozaffarian, M.E. Mussolino, G. Nichol, N.P. Paynter, E.Z. Soliman, P.D. Sorlie, N. Sotoodehnia, T.N. Turan, S.S. Virani, N.D. Wong, D. Woo, M.B. Turner, *Circulation* **125**, e2–e220 (2012)
7. T.E.P. Investigators, *N. Engl. J. Med.* **366**, 1287–1297 (2012)
8. T.H.V. Investigators, *N. Engl. J. Med.* **369**, 1406–1415 (2013)
9. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, U. Masiukiewicz, R. Pak, J. Thompson, G.E. Raskob, J.I. Weitz, *N. Engl. J. Med.* **369**, 799–808 (2013)
10. T. Xue, S. Ding, B. Guo, Y. Zhou, P. Sun, H. Wang, W. Chu, G. Gong, Y. Wang, X. Chen, Y. Yang, *J. Med. Chem.* **57**, 7770–7791 (2014)
11. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, A.L. Waldo, M.D. Ezekowitz, J.I. Weitz, J. Špinar, W. Ruzyllo, M. Ruda, Y. Koretsune, J. Betcher, M. Shi, L.T. Grip, S.P. Patel, I. Patel, J.J. Hanyok, M. Mercuri, E.M. Antman, *N. Engl. J. Med.* **369**, 2093–2104 (2013)
12. T.E. Investigators, *N. Engl. J. Med.* **363**, 2499–2510 (2010)
13. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, G. Breithardt, J.L. Halperin, G.J. Hankey, J.P. Piccini, R.C. Becker, C.C. Nessel, J.F. Paolini, S.D. Berkowitz, K.A.A. Fox, R.M. Califf, T. R. A. S. Committee, *N. Engl. J. Med.* **365**, 883–891 (2011)
14. N.M. Cerqueira, D. Gesto, E.F. Oliveira, D. Santos-Martins, N.F. Bras, S.F. Sousa, P.A. Fernandes, M.J. Ramos, *Arch. Biochem. Biophys.* **582**, 56–67 (2015)
15. M.L. Verdonk, J.C. Cole, M.J. Hartshorn, C.W. Murray, R.D. Taylor, *Proteins* **52**, 609–623 (2003)
16. Factor Xa Specific Inhibitor that Induces the Novel Binding Model in Complex with Human Fxa. (<http://www.rcsb.org/pdb/explore/explore.do?structureId=1IQI>)